EUCTR2020-003143-28-GB进行中（未招募）1 期
A First-in-Human, Double-Blind, Randomised, Vehicle Controlled Phase I/II Proof of Concept Study to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of BEN2293 in Patients with Mild to Moderate Atopic Dermatitis (AD).
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 130
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Males and females with mild to moderate atopic dermatitis (based on vIGA) free from other clinically significant illness or disease that may adversely affect the safety of the patient or the integrity of the study as determined by medical history, physical examination, safety laboratory and other assessments.
- •3. Patient is aged between18 to 65 years, inclusive.
- •4. Patient has a body mass index (BMI) of 18.0 to 30.0 kg/m2, inclusive.
- •5. Body weight of =50 kg.
- •6. History of atopic dermatitis for at least 6 months diagnosed by a dermatologist or GP.
- •8. A Validated Investigator’s Global Assessment (vIGA) score of 2 (mild) to 3 (moderate) at both Screening and Day -1.
- •9. Atopic dermatitis affecting between =5% to =15% Body Surface Area (BSA) of treatable skin (not including face, scalp, hands or soles of feet) at Screening and Day -1 for Cohorts 1 and 2, and between =5% to =30% BSA of treatable skin (not including face, scalp, hands or soles of feet) at Screening and Day -1 for subsequent cohorts.
- •10. History of AD associated pruritus with an itch score (NRS) of =4. The mean of the pruritus NRS scores (worst itch over the last 24 hours) obtained on Day -3, Day -2 and Day -1 during the emollient only washout phase will be used to assess inclusion.
- •11. Patients must be willing to stop applying their daily emollients and instead use the study emollient from at least 7 days prior to Day 1 and throughout their participation in the study.
- •12. Males must use a condom during the trial and for 3 months after their final dose study medication, In addition, their female partner of childbearing potential must be established on an additional method of highly effective contraception prior to dosing until 3 months following final dosing.
- •13. Female patients of childbearing potential must be established on a highly effective method of contraception prior to dosing until 3 months after last dose in combination with male partner’s use of a condom during the trial and for 3 months after the last dose. Patients must have a negative pregnancy test at Screening and Day 1.
- •14. Participant has a minimum of one atopic dermatitis area in a site suitable for biopsy.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 128
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 2
排除标准
- •1. Atopic dermatitis of such severity that the patient could not comply with the demands of the study and/or the patient is not a suitable candidate for a placebo controlled study, as per investigator’s discretion.
- •2. Any skin tattoo, scar, cuts, bruises, or other skin damage, including excessive UV exposure, at the possible IMP application sites.
- •3. Patients who have AD lesions affecting >3% untreatable areas (face, scalp, genitals, palms of hands or soles of feet).
- •4. Patients who have a source of itch solely or significantly from untreatable areas (face, scalp, genitals, palms of hands or soles of feet ).
- •5. Have concomitant skin disease or infection (e.g. acne, impetigo) or presence of skin comorbidities in the study area to be dosed that may interfere with study assessments.
- •6. Patients who are excessively hirsute in areas of skin to be dosed with study ointment.
- •7. Patients who are unwilling to stop hair removal by any means (including shaving, waxing or depilatory creams) to skin areas to be dosed with study ointment for 2 weeks prior to Day -1 and throughout the duration of the study.
- •12. Positive test for hepatitis B surface antigen (HBsAg), anti-hepatitis C antibody (anti HCV), human immunodeficiency virus I and II (anti-HIV I/II) or SARS-CoV-2 at Screening or Day -1.
- •17. Supine SBP <90 mmHg >140 mmHg , or DBP <50 mmHg or >90 mmHg after 5 minutes supine and after 3 minutes standing. One repeat is allowed if values are out of range.
- •22. Patients who have received phototherapy (e.g. UVA, UVB or PUVA therapy), or systemic therapy (e.g., immunosuppressants [such as cyclosporine, azathioprine, methotrexate], cytostatics) known or suspected to have an effect on AD, within 3 months prior to screening. All biologics must not have been used within 6 months prior to screening.
- •23. Patients who have received systemic corticosteroids (e.g. oral, intravenous, intraarticular, rectal) within 8 weeks prior to screening. Patients on a stable maintenance dose (over the preceding 3 months) of inhaled or intranasal corticosteroids may participate.
- •24. Patients treated with oral antihistamines within 7 days of screening; intranasal steroid, antihistamine or sodium cromoglycate sprays for the treatment of allergic rhinitis are acceptable.
- •25. Patients treated with topical calcineurin inhibitors within 1 month of screening.
研究者
相似试验
已完成
不适用
A First-in-Human, Double-Blind, Randomised, Vehicle-Controlled Phase I/II Proof of Concept Study to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of BEN2293 in Patients with Mild to Moderate Atopic Dermatitis.Atopic DermatitisNL-OMON51714BenevolentAI Bio Limited15
进行中（未招募）
1 期
Study of BEN2293 in Patients with Mild to Moderate Atopic DermatitisAtopic dermatitisEUCTR2020-003143-28-NLBenevolentAI Bio Limited280
进行中（未招募）
1 期
Study of BEN2293 in Patients with Mild to Moderate Atopic DermatitisAtopic dermatitisEUCTR2020-003143-28-HUBenevolentAI Bio Limited280
进行中（未招募）
1 期
Study of BEN2293 in Patients with Mild to Moderate Atopic DermatitisMedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858Atopic dermatitisEUCTR2020-003143-28-PLBenevolentAI Bio Limited280
已完成
不适用
A First-in-Human, Randomized, Double-Blinded, Placebo-Controlled Trial in Healthy Subjects to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single and Multiple Ascending Intravenous Dose Levels of ARGX-117 and Subcutaneous Dose Levels of ARGX-117 Co-Mixed with Recombinant Human Hyaluronidase PH20NL-OMON52853argenx BV112